Kelley D. Carlstrom, PharmD, BCOP’s Post

‘Studies reveal that #GLP-1 #medications could cut the risk of obesity-related cancers by a fifth.’ (The Times, 2024) Previous research recognised that #obesity #treatment with #bariatric #surgery also reduced the risk of obesity-related cancers (see ref), however, GLP-1 medications show a greater reduction in risk, even with less overall #weight loss.   Presented at the American Society of Clinical Oncology (ASCO) conference in Chicago, these new findings show promise for incorporating GLP-1 drugs into #cancer treatment protocols. 'GLP drugs are very promising and we certainly hope someday they will be a tool in cancer treatment. But before we can say that, we need rigorous clinical trials to test them,' said oncologist Dr. Sherry Shen. Click here to read the full study 👇 https://lnkd.in/eB59j4vR ref: Aminian A, Wilson R, Al-Kurd A, et al. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA. 2022;327(24):2423–2433

Exciting news from the ongoing SunRISe-1 study presented at the American Urological Association Annual Meeting! Updated results highlight TAR-200's efficacy and safety as a monotherapy for high-risk non-muscle-invasive bladder cancer patients who aren't responsive to BCG therapy. #AUA2024 #BladderCancer #ClinicalResearch #MedicalInnovation

#LiverCancer is a serious and often aggressive form of #cancer that begins in the cells of the liver. The most common type is #HepatocellularCarcinoma, which typically starts in #hepatocytes, the primary cells of the liver. Liver cancer can be difficult to detect in its early stages because symptoms often do not appear until the disease has progressed. Factors that increase the risk of developing liver cancer include chronic #HepatitisB or #HepatitisC infections, #cirrhosis, heavy #alcohol consumption, and exposure to #aflatoxins. Symptoms may include weight loss, loss of appetite, #jaundice, and abdominal pain. Early detection and treatment are crucial for improving outcomes, and options may include surgery, #livertransplant, chemotherapy, and targeted therapies. It's crucial to highlight that liver cancer is one of the fastest-growing cancer diagnoses in the world. This makes #LiverCancerAwarenessMonth an essential time to raise awareness and promote early detection. #Menagen #Pharma #CancerAwareness #HealthAwareness #CancerResearch #LiverHealth #Oncology #CancerTreatment

Exciting news in the fight against brain cancer! A recent Phase II clinical trial using the radiopharmaceutical 177Lu-Dotatate has shown significant progress in extending progression-free survival rates for patients with refractory meningiomas. Key findings include: Nearly 80% of patients remained progression-free after six months. This far exceeds the 26% benchmark from prior studies. 88.9% of patients had overall survival one-year post-treatment. With four infusions every eight weeks, this theranostic approach could represent a new, more effective option for treating aggressively growing meningiomas, where standard treatments like surgery and radiation have limitations. This therapy offers hope for those facing limited options, demonstrating both effectiveness and safety. Read more about the potential impact of radiopharmaceuticals in cancer treatment @ https://lnkd.in/d_ivHrRX 🔬 #PharmaceuticalResearch #Radiopharmaceuticals #CancerTreatment #Meningioma #ClinicalTrials #InnovativeMedicine #PharmaIndustry

We Care Your life Blooms... - Clutaflo 50: Bicalutamide Tablets 50mg Clutaflo 50 is a trusted medication used in the treatment of advanced prostate cancer. Each tablet contains 50mg of Bicalutamide, a non-steroidal anti-androgen that plays a crucial role in managing prostate cancer when used in combination with surgery or LHRH (luteinizing hormone-releasing hormone) analogues. Key Benefits: 1. Comprehensive Treatment: Designed to be used in combination with surgery or hormone therapy, providing a multi-faceted approach to cancer management. 2. Hormonal Control: Effectively blocks androgen receptors to help reduce tumor growth. 3. Improves Quality of Life: Aids in managing symptoms and slows disease progression, contributing to improved patient outcomes. Dosage and Administration: - #Clutaflo50 #Bicalutamide #ProstateCancer #CancerTreatment  #ProstateHealth #AdvancedProstateCancer #HormonalTherapy #CancerCare #Oncology #CancerSupport #MensHealth #ProstateCancerAwareness #FightCancer #CancerAwareness #HealthyLiving

We invite you to #publish an article on "Current Trends in Gynecologic Oncology," sharing your valuable insights and expertise. #cheating #Gynecologic #oncology #Ovarian #CancerCare #Endometrial #Cervical #Uterine #Vulvar #Vaginal #Pelvic #Chemotherapy #Radiation #Clinicaltrails

The IMPLEMENT study identified gaps in how both urologists and oncologists view first-line treatment intensification for metastatic castrate-sensitive prostate cancer. Additionally, there were also a number of differing beliefs, including whether there is enough clinical support. #OncologyResearch #ProstateCancer #HealthCareBarriers

Chemoablation with UGN-102 produced a high complete response rate in patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer (NMIBC) in the phase 3 ENVISION trial. https://brnw.ch/21wFVXD

Let’s have a quick look at clinical trials into novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   1. Valrubicin This is an intravesical chemotherapy agent, and until recently was the only FDA-approved agent for post-BCG treatment. It was approved in 1998 but not commonly used in real-world practice as it was not widely available and its efficacy was suboptimal.   “Of 90 patients, 19 (21%) had a complete response, including 7 who remained disease-free at the last evaluation, with a median follow-up of 30 months.” (Steinberg et al, The Journal of Urology, 2000).   Tomorrow: pembrolizumab   #medicalinnovation #bladdercancer #HIVEC #CombatMedical    

what percentage of these tumors become malignant because whether or not this procedure has brought new diseases to the patient that will have to be controlled clinically. What would be the patient's survival rate if there was no surgery? What is the survival rate after surgery?